My watch list
my.bionity.com  
Login  

Drug Response Dx concludes first round of financing with support from QIAGEN and High-Tech Gründerfonds

10-Jan-2013

Drug Response Dx GmbH (DRDx GmbH) concluded its first round of financing with High-Tech Gründerfonds and QIAGEN. The investment will serve to develop a biomarker test kit for rheumatoid arthritis treatment guidance with so-called TNF-alpha inhibitors. The test is secured by a patent platform exclusively in-licensed by the Max Planck Society.

One of the most important therapeutic options for RA involves inhibitors of the tumor necrosis factor (TNF-alpha). Due to cost, TNF-alpha inhibitors (€12,000–20,000 per patient/year) are only used today when conventional medications (€100–1,000 per patient/year) have proven ineffective over the course of months.

However, TNF-alpha inhibitors also only show success after three to six months at the earliest and only for 60–70% of patients. For so-called non-responders, it may often take up to a year of valuable time until effective medication is employed. Early, directed treatment, however, can lead to a complete remission of the disease. Patients, physicians, and sponsors are thus urgently seeking ways to improve the therapeutic decision process for rheumatoid arthritis.

The DRDx test kit based on protein biomarkers. It enables one to predict the individual effectiveness of TNF-alpha inhibitors for each RA patient before medication is given.

The founders of DRDx, Dr. Zoltán Konthur and Dr. Karl Skriner, have a background in internationally renowned scientific circles (Max Planck Society and Charité). Joining them is Dr. Jörg-M. Hollidt, an entrepreneur in the area of in vitro diagnostics (IVD) and CEO of in.vent Diagnostica GmbH. After several years of collaboration, the team has developed a biomarker set and from it the functional model of a routinely applicable test kit. This enables DRDx to identify with confidence those RA patients not susceptible to therapy with TNF-alpha inhibitors.

A proof of concept is already in place for the antibody-based verification procedure in an ELISA format (Enzyme Linked Immunosorbent Assay). The required biomarkers can also already be produced in high technical quality and fairly large quantities. “The next steps in development now concern the clinical validation of our diagnostic. In addition, we will test to what extent we can predict the effectiveness of TNF-alpha inhibitors for other indications and the effectiveness of non-TNF-alpha medications for RA,” says Managing Director Dr. Konthur.

Facts, background information, dossiers
  • Drug Response Dx GmbH
  • Max-Planck-Innovation
  • High-Tech Gründerfo…
More about DRDx
More about Max-Planck-Innovation
More about Qiagen
  • News

    QIAGEN and CENTOGENE to collaborate in bioinformatics for genetic diseases

    QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases. CENTOGENE is a leading rare disease company provi ... more

    Bristol-Myers Squibb and QIAGEN collaborate

    Bristol-Myers Squibb Company and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as  predictive or prognostic tools for  use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in cancer ... more

    QIAGEN joins CANCER-ID consortium for liquid biopsy workflows

    QIAGEN N.V. announced it has joined CANCER-ID, a public-private consortium aiming to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer. Rapid advances in the use of liquid biopsies, which enable cancer treatment and monitoring through ... more

  • Companies

    QIAGEN Benelux B.V.

    QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analy ... more

    QIAGEN Hamburg GmbH

    QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analy ... more

    QIAGEN N.V.

    QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analy ... more

More about High-Tech Gründerfonds Management
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE